Pulmatrix reports Q2 2026 results, cites progress on Eos SENOLYTIX merger
Cipla's Phase 3 plan for PUR1900 in India advances as Pulmatrix works toward closing its merger with Eos SENOLYTIX, expected in Q3 2026.
SEC filing
Latest
1 story
Sign inSign in1 story
Cipla's Phase 3 plan for PUR1900 in India advances as Pulmatrix works toward closing its merger with Eos SENOLYTIX, expected in Q3 2026.
SEC filing